Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Rhythm Pharmaceuticals announced on Tuesday that its hunger and severe obesity drug, setmelanotide, significantly reduced weight and hunger scores in people with Bardet-Biedl syndrome and Alström syndrome.
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.
Genentech, a Roche company, announced positive topline data from two identical Phase III trials of faricimab in diabetic macular edema (DME).
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
PRESS RELEASES